In ankylosing spondylitis (AS), structural damage that occurs as a result of syndesmophyte
formation and ankylosis of the vertebral column is irreversible. Structural damage is currently …

Background Secukinumab is an anti–interleukin-17A monoclonal antibody that has been
shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two …

Background In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs
and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of …

There has long been a need for biomarkers of disease activity in lupus nephritis (LN). Such
markers ideally would be capable of detecting early sub-clinical disease and could be used …

Objective To assess the safety and efficacy of secukinumab, a fully human monoclonal anti-interleukin-17A
antibody, in patients with rheumatoid arthritis (RA). Methods Patients (n=237) …

Excessive T helper cell function is a hallmark of systemic lupus erythematosus and
abnormalities of T helper cytokine profiles have been implicated in loss of immune tolerance, …

Objective To evaluate the effect of secukinumab, an interleukin-17A inhibitor, on clinical
signs and symptoms and radiographic changes through 2 years in patients with ankylosing …

Objective The premature atherosclerosis seen in patients with systemic lupus erythematosus
(SLE) is not explained by traditional risk factors. SLE disease activity, such as renal …

Pristane induces a lupus-like syndrome in nonautoimmune mice characterized by the
development of glomerulonephritis and lupus-associated autoantibodies. This is accompanied by …

OBJECTIVE: Pain and psychological distress are associated with fatigue, and social support
may play a buffering role in the adjustment to a chronic disease. Investigations of the …